In this video, Lisa Leypoldt, MD, University Medical Center Hamburg, Hamburg, Germany, shares results from the Phase II GMMG-CONCEPT trial (NCT03104842), which is evaluating the use of the quadruplet regimen isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in patients with high-risk newly diagnosed multiple myeloma (NDMM). The trial met its primary endpoint, and Dr Leypoldt reports on the rates of measurable residual disease (MRD) negativity and progression-free survival (PFS) observed. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
